Addressing Dementia Via Agitation-Centered Evaluation

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

July 13, 2017

Primary Completion Date

April 17, 2020

Study Completion Date

April 17, 2020

Conditions
Agitation in Patients With Dementia of the Alzheimer's TypeAlzheimer DiseaseAgitation,Psychomotor
Interventions
DRUG

AXS-05

AXS-05

DRUG

Bupropion

Bupropion

DRUG

Placebo

Placebo

Trial Locations (78)

3162

Axsome study site, Caulfield

10036

Axsome study site, New York

10128

Axsome study site, New York

10312

Axsome study site, Staten Island

11229

Axsome study site, Brooklyn

12208

Axsome Study Site, Albany

22903

Axsome Study Site, Charlottesville

23235

Axsome Study Site, Richmond

27103

Axsome Study Site, Winston-Salem

28211

Axsome Study Site, Charlotte

28270

Axsome study site, Charlotte

30030

Axsome study site, Decatur

30331

Axsome study site, Atlanta

32055

Axsome Study Site, Lake City

32127

Axsome Study Site, Port Orange

32502

Axsome study site, Pensacola

32703

Axsome Study Site, Apopka

32807

Axsome Study Site, Orlando

33009

Axsome study site, Hallandale

33012

Axsome study site, Hialeah

33066

Axsome Study Site, Coconut Creek

33122

Axsome study site, Miami

33165

Axsome study site, Miami

33437

Axsome study site, Boynton Beach

33467

Axsome Study Site, Greenacres City

33487

Axsome study site, Boca Raton

33609

Axsome study site, Tampa

33613

Axsome study site, Tampa

34609

Axsome study site, Spring Hill

39401

Axsome Study Site, Hattiesburg

44122

Axsome study site, Shaker Heights

45069

Axsome study site, Cincinnati

45459

Axsome Study Site, Dayton

46123

Axsome study site, Avon

60422

Axsome Study Site, Flossmoor

63005

Axsome study site, Chesterfield

63128

Axsome Study Site, St Louis

66212

Axsome Study Site, Overland Park

66606

Axsome Study Site, Topeka

70629

Axsome Study Site, Lake Charles

70808

Axsome study site, Baton Rouge

72209

Axsome Study Site, Little Rock

73112

Axsome Study Site, Oklahoma City

75071

Axsome Study Site, McKinney

75115

Axsome study site, DeSoto

76309

Axsome study site, Wichita Falls

80910

Axsome Study Site, Colorado Springs

83704

Axsome study site, Boise

84058

Axsome study site, Orem

85004

Axsome Study Site, Phoenix

85251

Axsome study site, Scottsdale

85258

Axsome study site, Scottsdale

85297

Axsome Study Site, Gilbert

85704

Axsome Study Site, Tucson

89102

Axsome study site, Las Vegas

89109

Axsome Study Site, Las Vegas

90720

Axsome Study Site, Los Alamitos

90806

Axsome study site, Long Beach

90807

Axsome study site, Long Beach

91303

Axsome study site, Canoga Park

91321

Axsome Study Site, Santa Clarita

91403

Axsome study site, Sherman Oaks

92503

Axsome study site, Riverside

92591

Axsome study site, Temecula

92626

Axsome study site, Costa Mesa

92705

Axsome study site, Santa Ana

93003

Axsome study site, Ventura

93065

Axsome study site, Simi Valley

93710

Axsome study site, Fresno

95821

Axsome study site, Sacramento

96817

Axsome Study Site, Honolulu

98007

Axsome study site, Bellevue

98201

Axsome Study Site, Everett

99202

Axsome study site, Spokane

06416

Axsome study site, Cromwell

06320

Axsome study site, New London

08540

Axsome Study Site, Princeton

08755

Axsome study site, Toms River

Sponsors
All Listed Sponsors
lead

Axsome Therapeutics, Inc.

INDUSTRY

NCT03226522 - Addressing Dementia Via Agitation-Centered Evaluation | Biotech Hunter | Biotech Hunter